ROCHE HOLDING AG |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 34.01 USD | +7.19% |
|
+1.58% | -5.26% |
| 02:55pm | Roche Teams Up With Ascidian Therapeutics for RNA Gene Editing Deal | DJ |
| 01:00pm | Roche partners with Ascidian Therapeutics to develop gene therapies | RE |
| Sales 2024 * | 6.06TCr 6.85TCr 5,71100Cr | Sales 2025 * | 6.4TCr 7.23TCr 6,03000Cr | Capitalization | 20TCr 22TCr 18,70300Cr |
|---|---|---|---|---|---|
| Net income 2024 * | 1.33TCr 1.5TCr 1,24900Cr | Net income 2025 * | 1.47TCr 1.67TCr 1,38900Cr | EV / Sales 2024 * | 3.51 x |
| Net Debt 2024 * | 1.41TCr 1.59TCr 1,32700Cr | Net Debt 2025 * | 900.05Cr 1.02TCr 85TCr | EV / Sales 2025 * | 3.24 x |
| P/E ratio 2024 * |
14.7
x | P/E ratio 2025 * |
13.3
x | Employees | 1,03,605 |
| Yield 2024 * |
3.99% | Yield 2025 * |
4.1% | Free-Float | 88.91% |
More Fundamentals
* Assessed data
More news
Latest transcript on Roche Holding AG
More recommendations
More press releases
More news
| 1 day | +7.19% | ||
| 1 week | +1.58% | ||
| Current month | +7.39% | ||
| 1 month | +3.34% | ||
| 3 months | +3.37% | ||
| 6 months | -3.41% | ||
| Current year | -5.26% |
1 week
34.01
34.72
1 month
31.2534.72
Current year
29.2737.27
1 year
29.2739.62
3 years
29.2753.30
5 years
29.2753.72
10 years
27.6053.72
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 49 | 01/03/01 | |
Severin Schwan
CHM | Chairman | 57 | 01/08/01 |
Alan Hippe
DFI | Director of Finance/CFO | 57 | 01/11/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bernard Poussot
BRD | Director/Board Member | 72 | 03/15/03 |
| Director/Board Member | 59 | - | |
| Director/Board Member | 66 | 01/96/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/24/17 | 34.32 | -1.15% | 0 |
| 14/24/14 | 34.72 | +1.25% | 46 |
| 13/24/13 | 34.29 | +0.65% | 0 |
| 12/24/12 | 34.07 | +2.04% | 370 |
| 11/24/11 | 33.39 | -0.27% | 29 |
Delayed Quote London S.E., June 12, 2024 at 07:01 pm IST
More quotes
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
245.5
CHF
Average target price
278.1
CHF
Spread / Average Target
+13.26%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +52.09% | 80TCr | |
| +40.58% | 63TCr | |
| -6.85% | 35TCr | |
| +17.00% | 32TCr | |
| +10.14% | 30TCr | |
| +16.74% | 24TCr | |
| +5.12% | 16TCr | |
| -5.82% | 15TCr | |
| -1.47% | 12TCr |
- Stock Market
- Equities
- ROG Stock
- 0TDF Stock
